300972 Stock Overview
Fujian Wanchen Biotechnology Co., Ltd engages in the research and development, cultivation, production, and sale of edible fungi in China.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 6/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Fujian Wanchen Biotechnology Group Co., Ltd. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CN¥27.06 |
52 Week High | CN¥47.53 |
52 Week Low | CN¥23.80 |
Beta | 0.082 |
1 Month Change | -9.29% |
3 Month Change | -22.11% |
1 Year Change | -31.25% |
3 Year Change | 45.17% |
5 Year Change | n/a |
Change since IPO | -0.88% |
Recent News & Updates
Recent updates
Shareholder Returns
300972 | CN Food | CN Market | |
---|---|---|---|
7D | 8.0% | 1.9% | 2.1% |
1Y | -31.3% | -20.2% | -14.2% |
Return vs Industry: 300972 underperformed the CN Food industry which returned -19.5% over the past year.
Return vs Market: 300972 underperformed the CN Market which returned -14.6% over the past year.
Price Volatility
300972 volatility | |
---|---|
300972 Average Weekly Movement | 7.5% |
Food Industry Average Movement | 6.8% |
Market Average Movement | 8.7% |
10% most volatile stocks in CN Market | 12.7% |
10% least volatile stocks in CN Market | 5.2% |
Stable Share Price: 300972's share price has been volatile over the past 3 months.
Volatility Over Time: 300972's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2011 | 1,670 | Li Qing Wang | www.vanchen.com |
Fujian Wanchen Biotechnology Co., Ltd engages in the research and development, cultivation, production, and sale of edible fungi in China. It offers flammulina velutipes; and crab-flavored, white jade, seafood mushrooms, etc. The company was founded in 2011 and is based in Zhangpu, China.
Fujian Wanchen Biotechnology Group Co., Ltd. Fundamentals Summary
300972 fundamental statistics | |
---|---|
Market cap | CN¥4.66b |
Earnings (TTM) | -CN¥82.93m |
Revenue (TTM) | CN¥9.29b |
0.5x
P/S Ratio-56.3x
P/E RatioIs 300972 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
300972 income statement (TTM) | |
---|---|
Revenue | CN¥9.29b |
Cost of Revenue | CN¥8.43b |
Gross Profit | CN¥864.11m |
Other Expenses | CN¥947.03m |
Earnings | -CN¥82.93m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Apr 27, 2024
Earnings per share (EPS) | -0.48 |
Gross Margin | 9.30% |
Net Profit Margin | -0.89% |
Debt/Equity Ratio | 117.0% |
How did 300972 perform over the long term?
See historical performance and comparison